株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Bcl 2様タンパク質1 :パイプライン製品の分析

Bcl 2 Like Protein 1 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 527286
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
Bcl 2様タンパク質1 :パイプライン製品の分析 Bcl 2 Like Protein 1 - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 59 Pages
概要

当レポートではBcl 2様タンパク質1を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

Bcl 2様タンパク質1;概要

Bcl 2様タンパク質1 ;治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AbbVie Inc
  • 武田薬品工業

薬剤プロファイル

休止中の製品

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AbbVie Inc, H2 2019
  • Pipeline by Ascentage Pharma Group Corp Ltd, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC1916TDB

Summary:

According to the recently published report 'Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H2 2019'; Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

The report 'Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H2 2019' outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 3 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Non-Small Cell Lung Cancer, Lymphoma, Small-Cell Lung Cancer, Solid Tumor, Chronic Lymphocytic Leukemia (CLL), Essential Thrombocythemia, Fibrosis, Hepatocellular Carcinoma, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Metastatic Liver Cancer, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Multiple Myeloma and Relapsed Multiple Myeloma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
  • The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Ascentage Pharma Group Corp Ltd
    • AstraZeneca Plc
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles
    • ABT-737 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APG-1252 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-0466 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DT-2216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • navitoclax dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Hormone-Sensitive Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products
  • Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2019: US patent granted for DEP Bcl2/xL inhibitor conjugates
      • May 30, 2019: AbbVie presents update on Navitoclax and additional research at the 2019 EHA Meetings
      • May 21, 2019: Scientists discover potential breakthrough in the understanding of tumor dormancy
      • Nov 13, 2018: Ascentage Pharma presenting new clinical data of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 at Asia Conference on Lung Cancer 2018 (ACLC)
      • Aug 31, 2018: AstraZeneca's DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination
      • May 21, 2018: Ascentage Pharma Announces Promising Phase 1 Interim Results Of APG-1252 At 2018 ASCO Annual Meeting
      • Feb 21, 2018: Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting
      • Jun 26, 2017: Ascentage Announces CFDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
      • Dec 26, 2016: Ascentage Announces FDA Grants Bcl-2/Bcl-XL inhibitor APG-1252 IND Approval for Treatment of Cancers
      • Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
      • Nov 16, 2011: New Drug Combo Targets Multiple Cancers
      • Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
      • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
      • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
      • May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top